Abstract
Adverse effects of antiresorptive therapy contribute to high rates of non-adherence to osteoporosis treatments. Gastrointestinal side effects are the most common cause of oral bisphosphonate discontinuation, and acute phase reactions are the most common adverse effect of IV bisphosphonate therapy. Popular press articles and social media often mischaracterize the prevalence of extremely rare bisphosphonate side effects like osteonecrosis of the jaw and atypical femur fractures. Learning about risk factors for these side effects can help prevent them by choosing appropriate candidates for therapy. Understanding of these side effects can help promote prompt and effective treatment. Knowing about the frequently overstated prevalence of these side effects can help guide evidence-based risk benefit discussions when deciding on treatment options to prevent the morbidity and mortality of devastating osteoporotic fractures while minimizing the risks of therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177–87.
Khan A, Morrison A, Hanley D, Felsenberg D, McCauley L, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2014;30(1):3–23.
Pimolbutr K, Porter S, Fedele S. Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-naïve patient: a comprehensive review of the literature. Biomed Res Int. 2018;2018:1–14.
Sacco R, Ball R, Barry E, Akintola O. The role of illicit drugs in developing medication-related osteonecrosis (MRONJ): a systematic review. Br J Oral Maxillofac Surg. 2021;59(4):398–406.
Nguyen H, Milat F, Ebeling P. A new contralateral atypical femoral fracture despite sequential therapy with teriparatide and strontium ranelate. Bone Rep. 2017;6:34–7.
Shane E, Burr D, Abrahamsen B, Adler R, Brown T, Cheung A, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2013;29(1):1–23.
Black D, Rosen C. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–62.
Black D, Abrahamsen B, Bouxsein M, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2018;40(2):333–68.
Black D, Geiger E, Eastell R, Vittinghoff E, Li B, Ryan D, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383(8):743–53.
Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract. 2020;26:1–46.
Reid I, Gamble G, Mesenbrink P, Lakatos P, Black D. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metabol. 2010;95(9):4380–7.
Lim S, Bolster M. What can we do about musculoskeletal pain from bisphosphonates? Cleve Clin J Med. 2018;85(9):675–8.
Crotti C, Watts N, De Santis M, Ceribelli A, Fabbriciani G, Cavaciocchi F, et al. Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxyvitamin D and previous oral bisphosphonate therapy. Endocr Pract. 2018;24(5):405–10.
Tian Y, Wang R, Liu L, Ma C, Lu Q, Yin F. Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report. BMC Musculoskelet Disord. 2016;17(1):72.
Khosla S, Bilezikian J, Dempster D, Lewiecki E, Miller P, Neer R, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metabol. 2012;97(7):2272–82.
Robinson D, Ali M, Pallares N, Tebé C, Elhussein L, Abrahamsen B, et al. Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis. J Bone Miner Res. 2021;36(5):820–32.
Goldshtein I, Rouach V, Shamir-Stein N, Yu J, Chodick G. Role of side effects, physician involvement, and patient perception in non-adherence with oral bisphosphonates. Adv Ther. 2016;33(8):1374–84.
Dömötör Z, Vörhendi N, Hanák L, Hegyi P, Kiss S, Csiki E, et al. Oral treatment with bisphosphonates of osteoporosis does not increase the risk of severe gastrointestinal side effects: a meta-analysis of randomized controlled trials. Front Endocrinol. 2020;11:573976.
Lanza F. Gastrointestinal adverse effects of bisphosphonates. Treat Endocrinol. 2002;1(1):37–43.
Lin D, Kramer J, Ramsey D, Alsarraj A, Verstovsek G, Rugge M, et al. Oral bisphosphonates and the risk of Barrettʼs esophagus: case–control analysis of US veterans. Am J Gastroenterol. 2013;108(10):1576–83.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jain, S., Camacho, P. (2021). Adverse Effects of Antiresorptive Therapy. In: Cusano, N.E. (eds) Osteoporosis. Springer, Cham. https://doi.org/10.1007/978-3-030-83951-2_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-83951-2_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-83950-5
Online ISBN: 978-3-030-83951-2
eBook Packages: MedicineMedicine (R0)